Valproic acid as anti-cancer drug

被引：87
作者：
Michaelis, Martin [1 ]
Doerr, Hans Wilhelm [1 ]
Cinatl, Jindrich, Jr. [1 ]
机构：
[1] Goethe Univ Frankfurt, Inst Med Virol, Zentrum Hyg, D-6000 Frankfurt, Germany
来源：
CURRENT PHARMACEUTICAL DESIGN | 2007年 / 13卷 / 33期
关键词：
valproic acid; HDAC; differentiation; angiogenesis; combination therapy; clinical studies; HISTONE DEACETYLASE INHIBITORS; TRANS-RETINOIC ACID; ACUTE MYELOID-LEUKEMIA; ACTIVATED-RECEPTOR-GAMMA; PROSTATE-SPECIFIC ANTIGEN; ACUTE MYELOGENOUS LEUKEMIA; FETAL HEMOGLOBIN-SYNTHESIS; APOPTOSIS-INDUCING LIGAND; PML NUCLEAR-BODIES; CANCER CELL-GROWTH;
D O I：
10.2174/138161207782360519
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The short chain fatty acid valproic acid (VPA, 2-propylpetanoic acid) is approved for the treatment of epilepsia, bipolar disorders and migraine and clinically used for schizophrenia. In 1999, the first clinical anti-cancer trial using VPA was initiated. Currently, VPA is examined in numerous clinical trials for different leukaemias and solid tumour entities. In addition to clinical assessment, the experimental examination of VPA as anti-cancer drug is ongoing and many questions remain unanswered. Although other mechanisms may also contribute to VPA-induced anti-cancer effects, inhibition of histone deacetylases appears to play a central role. This review focuses on recent developments regarding the anti-cancer activity of VPA.
引用
收藏
页码：3378 / 3393
页数：16
相关论文
共 254 条
  • [1] Abdul M, 2001, ANTICANCER RES, V21, P2045
  • [2] Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo
    Achachi, A
    Florins, A
    Gillet, N
    Debacq, C
    Urbain, P
    Foutsop, GM
    Vandermeers, F
    Jasik, A
    Reichert, M
    Kerkhofs, P
    Lagneaux, L
    Burny, A
    Kettmann, R
    Willems, L
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (29) : 10309 - 10314
  • [3] Impaired methionine synthesis and hypomethylation in rats exposed to valproate during gestation
    Alonso-Aperte, E
    Ubeda, N
    Achón, M
    Pérez-Miguelsanz, J
    Varela-Moreiras, G
    [J]. NEUROLOGY, 1999, 52 (04) : 750 - 756
  • [4] Valproic acid does not affect markers of human immunodeficiency virus disease progression
    Ances, Beau M.
    Letendre, Scott
    Buzzell, Maria
    Marquie-Beck, Jennifer
    Lazaretto, Deborah
    Marcotte, Thomas D.
    Grant, Igor
    Ellis, Ronald J.
    [J]. JOURNAL OF NEUROVIROLOGY, 2006, 12 (05) : 403 - 406
  • [5] Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid:: a case report
    Ånensen, NA
    Skavland, J
    Stapnes, C
    Ryningen, A
    Borresen-Dale, AL
    Gjertsen, BT
    Bruserud, O
    [J]. LEUKEMIA, 2006, 20 (04) : 734 - 736
  • [6] Peroxisome proliferator-activated receptor γ regulates E-cadherin expression and inhibits growth and invasion of prostate cancer
    Annicotte, Jean-Sebastien
    Iankova, Irena
    Miard, Stephanie
    Fritz, Vanessa
    Sarruf, David
    Abella, Anna
    Berthe, Marie-Laurence
    Noel, Daniele
    Pillon, Arnaud
    Iborra, Francois
    Dubus, Pierre
    Maudelonde, Thierry
    Culine, Stephane
    Fajas, Lluis
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (20) : 7561 - 7574
  • [7] Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D Ligands by the histone deacetylase inhibitor sodium valproate
    Armeanu, S
    Bitzer, M
    Lauer, UM
    Venturelli, S
    Pathil, A
    Krusch, M
    Kaiser, S
    Jobst, K
    Smirnow, I
    Wagner, A
    Steinle, A
    Salih, HR
    [J]. CANCER RESEARCH, 2005, 65 (14) : 6321 - 6329
  • [8] Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells
    Bai, Jirong
    Demirjian, Aram
    Sui, Jianhua
    Marasco, Wayne
    Callery, Mark P.
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 348 (04) : 1245 - 1253
  • [9] Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays
    Baltes, Steffen
    Fedrowitz, Maren
    Tortos, Carlos Luna
    Potschka, Heidrun
    Loescher, Wolfgang
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 320 (01) : 331 - 343
  • [10] Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
    Bauer, Stefan
    Groh, Veronika
    Wu, Jun
    Steinle, Alexander
    Phillips, Joseph H.
    Lanier, Lewis L.
    Spies, Thomas
    [J]. JOURNAL OF IMMUNOLOGY, 2018, 200 (07) : 2231 - 2233
12345678910